Acute Agitation and Aggression Treatment Market to Garner US$ 7.09 Billion and Growing at a CAGR of 5.1% by 2031

According to the report, the global 𝐚𝐜𝐮𝐭𝐞 𝐚𝐠𝐢𝐭𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐚𝐠𝐠𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 market was valued at US$ 4.10 Bn in 2020 and is projected to cross the value of US$ 7.09 Bn at a CAGR of 5.1% from 2021 to 2031. Agitation can be defined as excessive motor or verbal behavior, which can further escalate to aggression. Physical agitation and aggression are manifested in the form of throwing objects toward people, and verbal agitation and aggression manifests as abuses and threats. Acute agitation and aggression are the common symptoms of mental illnesses such as schizophrenia, dementia, bipolar disorder, alcohol withdrawal, and depression.

Changing attitude toward diagnosis of agitation and aggression among mentally ill patients and rise in awareness about treatments is the key factor projected to drive the global acute agitation and aggression treatment market during the forecast period.

North America held major share of the global acute agitation and aggression treatment market in 2020. Focus on spreading awareness about treatment related to agitation and aggression among people, increase in economic burden of mental illness, well-established healthcare infrastructure, presence of leading players, and rise in focus of these players on research & development boost the growth of the market in North America.

The acute agitation and aggression treatment market in Asia Pacific is expected to expand at a CAGR of 6.1% from 2021 to 2031. Growth of the market in the region can be attributed to increase in the geriatric population, rise in prevalence of mental illnesses such as schizophrenia & bipolar disorder, and focus of market players on India and Japan to exploit opportunities in the emerging markets.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐚 𝐬𝐚𝐦𝐩𝐥𝐞 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 (𝐔𝐬𝐞 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐞 𝐌𝐚𝐢𝐥 𝐈𝐝 𝐟𝐨𝐫 𝐐𝐮𝐢𝐜𝐤 𝐑𝐞𝐬𝐩𝐨𝐧𝐬𝐞) - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=72345

𝐈𝐧𝐜𝐫𝐞𝐚𝐬𝐞 𝐢𝐧 𝐈𝐧𝐜𝐢𝐝𝐞𝐧𝐜𝐞 𝐨𝐟 𝐃𝐞𝐦𝐞𝐧𝐭𝐢𝐚 𝐢𝐧 𝐆𝐞𝐫𝐢𝐚𝐭𝐫𝐢𝐜 𝐏𝐨𝐩𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐭𝐨 𝐃𝐫𝐢𝐯𝐞 𝐌𝐚𝐫𝐤𝐞𝐭

Dementia is a condition, which results in decline in memory and other cognitive functions, affecting daily functioning. This condition is more common among the geriatric population. According to the WHO, dementia is expected to affect 82 million people in 2030 and 152 million people in 2050 globally. According to Alzheimer's Association Report, an estimated 5.8 million people in the U.S. aged 65 and over lived with Alzheimer's disease in 2020. The number of people aged 65 and older with Alzheimer's dementia is projected to reach 13.8 million by 2050 owing to increase in the geriatric population. Agitation and aggression are considered the most common symptoms experienced by dementia patients. Therefore, increase in incidence of dementia among the geriatric population is likely to boost the growth of the global acute agitation and aggression treatment during the forecast period.

𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐥𝐨𝐠𝐢𝐜 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡𝐞𝐬 (𝐃𝐫𝐮𝐠𝐬) 𝐇𝐞𝐥𝐝 𝐌𝐚𝐣𝐨𝐫 𝐒𝐡𝐚𝐫𝐞 𝐨𝐟 𝐆𝐥𝐨𝐛𝐚𝐥 𝐌𝐚𝐫𝐤𝐞𝐭

In terms of treatment approach, the global acute agitation and aggression treatment market has been classified into behavioral approaches, environmental interventions, and pharmacologic approaches (drugs). The pharmacologic approaches (drugs) segment has been split into lorazepam, chlorpromazine, quetiapine, droperidol, olanzapine, ziprasidone, and others. The pharmacologic approaches (drugs) segment dominated the global market in 2020. In emergency care settings, pharmacological approach reduces agitation or aggressive behavior without causing excessive sedation, and ideally avoid invasive administration routes. Traditionally, the following classes of medications have been used to treat agitation: first-generation antipsychotics (FGAs), benzodiazepines (BZDs), and second-generation antipsychotics (SGAs). The growth of the segment can be attributed to the effectiveness of these drugs in controlling agitation and aggression.

𝐏𝐫𝐞𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐟𝐨𝐫 𝐎𝐫𝐚𝐥 𝐑𝐨𝐮𝐭𝐞 𝐟𝐨𝐫 𝐀𝐜𝐮𝐭𝐞 𝐀𝐠𝐢𝐭𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐀𝐠𝐠𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭

Based on route of administration, the global acute agitation and aggression treatment market has been categorized into oral, intramuscular, and others. The oral segment dominated the global acute agitation and aggression treatment market in 2020, and the trend is anticipated to continue during the forecast period. The growth of the segment can be attributed to the preference for oral medications for the treatment of agitation and aggression

𝐒𝐜𝐡𝐢𝐳𝐨𝐩𝐡𝐫𝐞𝐧𝐢𝐚 𝐃𝐨𝐦𝐢𝐧𝐚𝐭𝐞𝐝 𝐆𝐥𝐨𝐛𝐚𝐥 𝐌𝐚𝐫𝐤𝐞𝐭

In terms of indication, the global acute agitation and aggression treatment market has been segregated into schizophrenia, dementia, bipolar disorder, depression, drug-induced agitation & aggression, alcohol withdrawal, and others. The schizophrenia segment accounted for major share of the global acute agitation and aggression treatment market in 2020. The segment's dominance can be attributed to the availability of approved drugs for the treatment of agitation in schizophrenia.

𝐇𝐨𝐬𝐩𝐢𝐭𝐚𝐥𝐬 & 𝐀𝐦𝐛𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐒𝐮𝐫𝐠𝐢𝐜𝐚𝐥 𝐂𝐞𝐧𝐭𝐞𝐫𝐬 𝐭𝐨 𝐛𝐞 𝐌𝐚𝐣𝐨𝐫 𝐄𝐧𝐝-𝐮𝐬𝐞𝐫

Based on end-user, the global acute agitation and aggression treatment market has been divided into hospitals & ambulatory surgical centers, psychiatric care facilities, and others. The hospitals & ambulatory surgical centers segment accounted for a major share of the global acute agitation and aggression treatment market in 2020. The segment is projected to be driven by increase in mental illness patient visits for emergency treatment.

𝐁𝐮𝐲 𝐭𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 | 𝐈𝐦𝐦𝐞𝐝𝐢𝐚𝐭𝐞 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐀𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐚𝐭 - https://www.transparencymarketresearch.com/checkout.php?rep_id=72345<ype=S

𝐍𝐨𝐫𝐭𝐡 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 𝐭𝐨 𝐃𝐨𝐦𝐢𝐧𝐚𝐭𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐌𝐚𝐫𝐤𝐞𝐭; 𝐀𝐬𝐢𝐚 𝐏𝐚𝐜𝐢𝐟𝐢𝐜 𝐭𝐨 𝐎𝐟𝐟𝐞𝐫 𝐒𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐭 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬

In terms of region, the global acute agitation and aggression treatment market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is projected to account for a prominent share of the global acute agitation and aggression treatment market during the forecast period. Significant investments by the market players in research & development leading to a strong pipeline of drugs for the treatment of agitation in mental illness are the major factors driving the market in North America.

The market in Europe is anticipated to expand at a high CAGR in the near future, owing to significant number of non-government organizations focused on spreading awareness about the treatment for mental illness. For instance, the Alzheimer's Society in the U.K., a charity organization that creates campaigns to spread awareness about the signs of agitation and aggression in Alzheimer's, funds research efforts to find a cure for the disease in the region.

The acute agitation and aggression treatment market in Asia Pacific is expected to grow at a rapid pace in the near future. This can be attributed to increase in the geriatric population, rise in prevalence of mental illness such as schizophrenia and bipolar disorder, and focus of market players on India and Japan to exploit opportunities in the emerging markets.

𝐆𝐫𝐨𝐰𝐭𝐡 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬

Key players operating in the global acute agitation and aggression treatment market are Eli Lilly and Company, Pfizer, Inc., GlaxoSmithKline, Otsuka Holdings Co., Ltd., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, and H. Lundbeck A/S, Sun Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Bausch Health Companies, Inc., Apotex, Inc., and Aurobindo Pharma. These companies engage in research & development to develop novel products in order to expand product offerings and customer base. For instance, in April 2021, Otsuka and Lundbeck announced a decision to continue a phase III clinical trial of Brexpiprazole for the treatment of agitation in patients with Alzheimer's-type dementia.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐜𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=72345

𝐆𝐥𝐨𝐛𝐚𝐥 𝐀𝐜𝐮𝐭𝐞 𝐀𝐠𝐢𝐭𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐀𝐠𝐠𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧

𝐀𝐜𝐮𝐭𝐞 𝐀𝐠𝐢𝐭𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐀𝐠𝐠𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭, 𝐛𝐲 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡

𝐁𝐞𝐡𝐚𝐯𝐢𝐨𝐫𝐚𝐥 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡𝐞𝐬
𝐄𝐧𝐯𝐢𝐫𝐨𝐧𝐦𝐞𝐧𝐭𝐚𝐥 𝐈𝐧𝐭𝐞𝐫𝐯𝐞𝐧𝐭𝐢𝐨𝐧𝐬
𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐥𝐨𝐠𝐢𝐜 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡𝐞𝐬 (𝐃𝐫𝐮𝐠𝐬)
Lorazepam
Chlorpromazine
Quetiapine
Droperidol
Olanzapine
Ziprasidone
Others

𝐀𝐜𝐮𝐭𝐞 𝐀𝐠𝐢𝐭𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐀𝐠𝐠𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭, 𝐛𝐲 𝐈𝐧𝐝𝐢𝐜𝐚𝐭𝐢𝐨𝐧

Schizophrenia
Dementia
Bipolar Disorder
Depression
Drug-induced Agitation & Aggression
Alcohol Withdrawal
Others

𝐀𝐜𝐮𝐭𝐞 𝐀𝐠𝐢𝐭𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐀𝐠𝐠𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭, 𝐛𝐲 𝐑𝐨𝐮𝐭𝐞 𝐨𝐟 𝐀𝐝𝐦𝐢𝐧𝐢𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧

Oral
Intramuscular
Others

𝐀𝐜𝐮𝐭𝐞 𝐀𝐠𝐢𝐭𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐀𝐠𝐠𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭, 𝐛𝐲 𝐄𝐧𝐝-𝐮𝐬𝐞𝐫

Hospitals & Ambulatory Surgical Centers
Psychiatric Care Facilities
Others

𝐌𝐨𝐫𝐞 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 -

𝐔𝐫𝐢𝐧𝐚𝐫𝐲 𝐂𝐚𝐭𝐡𝐞𝐭𝐞𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 - https://www.einpresswire.com/article/576040433/urinary-catheters-market-size-is-expected-to-reach-us-5-1-billion-and-growing-at-4-5-cagr-by-2028

𝐃𝐍𝐀 𝐓𝐞𝐬𝐭 𝐊𝐢𝐭𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 - https://www.globenewswire.com/news-release/2022/04/13/2421920/0/en/DNA-Test-Kits-Market-to-Cross-US-2-7-Bn-Mark-by-2030-TMR-Report.html

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬

Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.